Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Stryker Corporation SYK

Healthcare — Medical Devices
S&P 500 Member Dividend Champion (5y) Cash Flow Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
586.13
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 3 — — 2 — — 3 — — 3 —
Insider Ownership
5.87%

Capital & Financial Ratios

Market Cap
105,480.00
Revenue
25,837.00
Net Income
3,729.00
Free Cash Flow
4,702.00
Net Debt
11,466.00
Current Ratio
2.16
Debt/Equity
0.62
P/E ratio
28.28
P/S ratio
4.08
P/B ratio
4.40
Past 5Y EPS Growth
7.20%
This Y EPS Growth
10.03%
Next Y EPS Growth
11.57%
Next 5Y EPS Growth
10.94%
in millions of $

Dividends

Payout Ratio
0.42
Annual Dividend Rate
3.00
Annual Dividend Yield
0.77%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 3.60
—
—
—
2025 3.40
—
—
—
—
2024 3.24
—
—
—
—
2023 3.05
—
—
—
—
2022 2.84
—
—
—
—
2021 2.59
—
—
—
—
2020 2.36
—
—
—
—
2019 2.14
—
—
—
—
2018 1.93
—
—
—
—
2017 1.75
—
—
—
—
2016 1.57
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 3,053.00 4,493.00 4,100.00 3,476.00
Receivables 3,765.00 3,987.00 4,039.00 3,743.00
Inventory 4,843.00 4,774.00 5,310.00 5,521.00
Other — — — —
12,518.00 14,847.00 14,755.00 14,418.00
2023 2024 2025 Q'26
Payables 1,517.00 1,679.00 1,799.00 1,663.00
ST’ Debt 2,094.00 1,409.00 1,000.00 750.00
Other — — — —
7,921.00 7,616.00 7,794.00 6,684.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 6,020.00 6,589.00 — —
—
’25 5,866.00 6,022.00 6,057.00 7,171.00
25,116.00
’24 5,243.00 5,422.00 5,494.00 6,436.00
22,595.00
’23 4,778.00 4,996.00 4,909.00 5,815.00
20,498.00
’22 4,275.00 4,493.00 4,479.00 5,202.00
18,449.00
’21 3,953.00 4,294.00 4,160.00 4,701.00
17,108.00
’20 3,588.00 2,764.00 3,737.00 4,262.00
14,351.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 581.00 1,261.00 — —
—
’25 250.00 1,111.00 1,540.00 2,143.00
5,044.00
’24 204.00 633.00 1,474.00 1,931.00
4,242.00
’23 445.00 688.00 1,050.00 1,528.00
3,711.00
’22 203.00 529.00 889.00 1,003.00
2,624.00
’21 452.00 878.00 933.00 1,000.00
3,263.00
’20 591.00 620.00 829.00 1,237.00
3,277.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 415.00 1,059.00 — —
—
’25 127.00 928.00 1,518.00 1,710.00
4,283.00
’24 37.00 481.00 1,304.00 1,665.00
3,487.00
’23 315.00 536.00 902.00 1,383.00
3,136.00
’22 84.00 386.00 751.00 815.00
2,036.00
’21 369.00 772.00 803.00 794.00
2,738.00
’20 447.00 511.00 760.00 1,072.00
2,790.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.93 3.30 — —
—
’25 1.69 2.29 2.22 2.20
8.40
’24 2.05 2.14 2.16 1.41
7.76
’23 1.54 1.93 1.80 2.98
8.25
’22 0.84 1.72 2.14 1.47
6.17
’21 0.79 1.55 1.14 1.73
5.21
’20 1.30 (0.22) 1.63 1.49
4.20

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 188.84 243.79 292.43 329.16 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 280.43 306.93 398.20 406.19 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51,000 52,000 53,000 56,000 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.36 0.39 0.43 0.45 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18,449.00 20,498.00 22,595.00 25,116.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.76% 63.70% 63.91% 63.96% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,683.00 3,673.00 3,492.00 4,514.00 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.54% 17.92% 15.45% 17.97% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,358.00 3,165.00 2,993.00 3,246.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 998.00 1,028.00 1,050.00 1,193.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 48.78 54.00 59.30 65.71 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 6.23 8.34 7.86 8.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.94 9.78 11.13 13.20 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.55) (1.51) (1.98) (1.99) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.38 8.26 9.15 11.21 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.93 48.98 54.16 58.66 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 378.20 379.60 381.00 382.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.49 35.52 45.87 41.40 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.04 5.49 6.07 5.35 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.60 6.05 6.65 5.99 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.65 5.97 6.47 5.82 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51.16 39.03 41.95 34.11 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,624.00 3,711.00 4,242.00 5,044.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (588.00) (575.00) (755.00) (761.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,036.00 3,136.00 3,487.00 4,283.00 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,972.00 4,597.00 7,231.00 6,961.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,048.00 12,995.00 13,597.00 15,859.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11,120.00 9,942.00 9,104.00 11,759.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16,616.00 18,593.00 20,634.00 22,420.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.59% 8.24% 7.22% 7.15% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.40% 8.52% 7.75% 8.94% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.97% 17.98% 15.26% 15.08% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Stryker Corporation (SYK), a medtech powerhouse in orthopedics and surgical equipment, has delivered impressive fundamentals amid an aging population’s rising healthcare demands. Revenue has doubled since 2016 to $22.6 billion in 2023, with a robust 42% rebound post-pandemic and projections for $59.30 per share in 2024. Profitability shines through stable 64% gross margins, EBT surging 30% to $3.7 billion, and EPS poised to more than double to $12.27 by 2026, underpinned by strong free cash flow at $11.21 per share in 2025 estimates—fueling dividends, buybacks, and growth without balance sheet strain.

The stock has mirrored this strength, rising 222% since 2016 alongside revenue and EPS growth, trading at a forward 42x PE that could compress to 30x by 2026. Acquisitions like Wright Medical and Vocera have bolstered orthopedics and AI communications, with valuations like EV/FCF at 34x reasonable for its 10%+ ROIC consistency. A cautionary note: heavy insider selling exceeds $500 million with no buys, warranting watchfulness despite likely personal motivations.

Analysts project 19% mean upside, with revenue hitting $32 billion by 2028 (11% CAGR) and EPS at $16.09, driven by recurring disposables revenue and tailwinds from boomer retirements. Risks like policy shifts loom, but Stryker’s moat positions it as a quality compounder—worth holding for patient investors eyeing earnings beats in a volatile market.

Read full commentary →

Stryker Corporation (SYK) Latest News

News by impact score

Fine-tune

18 Sep

3 www.trefis.com, 8:33 AM
Intuitive Surgical faces questions over offsetting revenue from lower per-surgery pricing on its robotic systems. The strategy could shift volumes or margins in minimally invasive procedures. Stryker competes in adjacent surgical robotics and orthopedics segments where pricing pressure or adoption changes may affect market share. Competitor pricing moves in robotic surgery create moderate positioning pressure for Stryker without altering its core trajectory.

17 Sep

3 , 11:00 AM
Stryker expands foot and ankle offerings with Prophecy and smartHEX innovations. Targeted orthopedic product expansions can lift segment revenue and positioning without broad company-wide shifts.

4 Sep

3 , 2:36 PM
Stryker acquires ZuriMED to integrate FiberLocker technology and strengthen its shoulder portfolio. ZuriMED acquisition adds targeted shoulder technology with moderate potential to affect Stryker product positioning.

3 Sep

4 , 1:37 PM
Stryker launches FDA-cleared surgical app for Apple Vision Pro. FDA-cleared Vision Pro app marks significant product launch advancing Stryker surgical technology.

2 Sep

3 , 5:32 PM
Stryker Q2 results face comparison to diversified medical devices and supplies peers on financial metrics and market positioning. Q2 peer comparison supplies performance context that may shift short-term investor focus on Stryker without major strategic shifts.

3 www.medtechdive.com, 6:00 AM
Enovis acquires eCential Robotics to advance development of surgical orthopedic robots, intensifying competition against Stryker in the ortho robotics segment. Rival Enovis gains robotics capabilities that may erode Stryker's market position over time.

1 Sep

4 , 10:10 AM
Stryker Corporation acquires ZuriMED to expand its shoulder care portfolio. Acquisition marks major strategic expansion of Stryker shoulder care offerings.

4 , 9:05 AM
Stryker launches first FDA-authorized surgical application for Apple Vision Pro, demonstrated during hip arthroscopy at a top academic medical center. Pioneering FDA-cleared Vision Pro surgical app marks major product innovation that can shift Stryker's competitive position in medical technology.

3 , 1:06 PM
Stryker gains FDA approval for new surgery software and completes first procedure using it. FDA clearance plus first clinical use of new software supports incremental gains in product innovation and market positioning.

3 www.medtechdive.com, 1:02 PM
Stryker buys ZuriMED to add rotator cuff repair technology to its portfolio. Acquisition adds specialized orthopedic technology that may lift product offerings and competitive stance in shoulder repair.

31 Aug

3 , 4:05 PM
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering. Acquisition targets targeted enhancement of Stryker shoulder portfolio through ZuriMED addition.

25 Aug

4 www.trefis.com, 11:08 AM
Stryker Corporation places a hospital bet that reframes the stock narrative around Intuitive Surgical. Stryker hospital investment directly shifts competitive dynamics and investor views versus Intuitive Surgical.

21 Aug

3 , 12:11 PM
Stryker Corporation wins a US$100 million defense contract that could shift investor perceptions of the company's growth prospects. A single $100 million contract adds revenue but remains limited relative to Stryker's overall scale and core medical device operations.

13 Aug

3 , 1:49 PM
Stryker Corporation growth is improving but execution risks persist, raising questions whether SYK is worth buying. Improving growth offset by execution risks points to moderately noticeable influence on SYK trajectory.

3 , 1:49 PM
Stryker reports Q2 recovery with updated guidance, prompting assessment of potential for stronger second half results. Q2 recovery and guidance updates typically produce moderate effects on near-term financial outlook and investor sentiment.

3 , 1:49 PM
Stryker shares rose 13.6% over three months as recovery momentum builds, leaving uncertainty about subsequent performance and direction. Strengthening recovery supports near-term sentiment and stock movement without shifting long-term fundamentals.

11 Aug

3 , 5:23 PM
Stryker posts strong quarterly results after prior weakness, but questions arise over sustainability and hidden costs of the rebound. Stryker recovery raises cost concerns that may moderately affect financial outlook and sentiment without altering core trajectory.

3 Aug

4 transcript www.fool.com, 8:16 PM
Stryker Corporation released its Q2 2026 earnings call transcript covering financial results, segment performance, and management commentary on operations and outlook. Earnings call delivers detailed quarterly results and guidance that directly shape investor views and near-term stock movement for SYK.

1 Aug

4 , 12:12 PM
Stryker reports strong Q2 earnings, raises full-year guidance, and advances cyber incident recovery, supporting improved investor sentiment and stock performance. Strong Q2 earnings and raised guidance signal sustained revenue growth and operational recovery that can materially lift Stryker's valuation and trajectory.

31 Jul

4 , 1:04 AM
Stryker posted 9% organic growth in Q2 2026 and raised full-year guidance. Strong 9% organic growth with raised guidance signals major positive shift in revenue trajectory and investor sentiment.

3 , 11:31 PM
Stryker faces Q2 supply chain disruptions that weigh on growth outlook despite margin expansion. Supply chain disruptions and margin shifts point to moderate effects on Stryker's growth and operations.

3 transcript www.marketbeat.com, 11:03 PM
Stryker Q2 earnings call highlights detail financial results, operational updates, and forward guidance for the company. Q2 earnings updates and guidance may moderately influence financial performance outlook and investor sentiment.

3 , 11:23 AM
Stryker (SYK) shares plunge today on negative developments affecting the stock. Plunging share price signals negative sentiment likely to influence near-term market performance.

3 www.medicaldevice-network.com, 7:23 AM
Stryker Corporation reported $6.6 billion Q2 revenue and emphasized operational resilience after a cyberattack. Q2 revenue beat combined with cyberattack recovery points to steady financials but limited strategic shifts.

30 Jul

3 transcript www.fool.com, 8:30 PM
Stryker (SYK) held its Q2 2026 earnings call covering financial results, segment performance, and forward outlook. Quarterly earnings details and guidance typically influence near-term sentiment and valuation without fundamentally shifting long-term strategy.

3 , 6:00 PM
Stryker Q2 earnings release compares key financial metrics directly to Wall Street consensus estimates. Q2 earnings metric comparisons can influence near-term stock sentiment but rarely signal transformative strategic or competitive shifts.

3 , 5:25 PM
Stryker (SYK) reported Q2 earnings and revenues that exceeded analyst estimates. Q2 earnings beat signals moderate positive financial performance without major strategic changes.

3 , 4:30 PM
Stryker posted Q2 CY2026 sales in line with estimates, but the stock declined after the report. In-line sales accompanied by a stock drop point to moderate investor concerns likely affecting near-term sentiment.

3 , 4:05 PM
Stryker Corporation released its second quarter 2026 operating results. Quarterly results deliver key performance metrics that can shift near-term investor views and valuation.

3 , 12:40 PM
ISRG advances robotic surgery systems beyond urology, intensifying competition with SYK in broader surgical robotics and potentially shifting market share away from Stryker's offerings. ISRG's expansion in non-urology robotics creates moderate competitive pressure on SYK's surgical device segment without immediate fundamental disruption.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us